top of page
BIO 2026 Debrief: Why Privacy-First, Domain-Specific AI Is Gaining Traction
BIO 2026 in San Diego brought together a diverse cross-section of global biotechnology, pharmaceutical research, manufacturing and clinical organizations, providing a valuable snapshot of how artificial intelligence is being evaluated and adopted across the drug discovery landscape. Across four days of meetings and discussions, one message became increasingly clear: the conversation has shifted beyond whether AI merely has a role in drug discovery to how it can best deliver m
11 minutes ago3 min read
QIMR Berghofer and Qubigen Report Promising Experimental Validation Results in Ongoing AI-Driven Cancer Discovery Collaboration
Qubigen is pleased to share encouraging progress from its ongoing collaboration with QIMR Berghofer. The partnership combines QIMR Berghofer’s expertise in translational cancer biology with Qubigen’s privacy-preserving Federated AI platform to identify novel small-molecule candidates targeting tumorigenesis and cancer progression. The project is now advancing from computational discovery and early experimental validation into the AI optimization and hit-to-lead acceleration p
May 282 min read
Qubigen Collaborates with Dr. Srinivas Viswanathan at Dana-Farber Cancer Institute on Novel Kidney Cancer Research
Qubigen is pleased to report on a research collaboration with Dr. Srinivas Viswanathan and his team at Dana-Farber Cancer Institute. The project focuses on the discovery of novel small-molecule candidates for a rare and aggressive type of kidney cancer. Dr. Srinivas Viswanathan Computational Modeling and Federated AI Powered Design Using Qubigen’s privacy-preserving Federated AI platform, we have applied advanced computational modeling to identify and rank potential compounds
May 112 min read
bottom of page